Commentary on "A roadmap for the prevention of dementia II. Leon Thal Symposium 2008." Who may benefit from disease-modifying studies in Alzheimer's disease?

Alzheimers Dement. 2009 Mar;5(2):147-8. doi: 10.1016/j.jalz.2009.01.007.

Authors

Serge Gauthier¹, Judes Poirier

Affiliation

¹ Department of Neurology and Neurosurgery, and McGill Center for Studies in Aging, McGill University, and Douglas Mental Health University Institute, Montreal, Quebec, Canada. [email protected]

PMID: 19328447
DOI: 10.1016/j.jalz.2009.01.007

No abstract available

Publication types

Editorial
Comment

MeSH terms

Age of Onset
Aged
Alzheimer Disease / drug therapy*
Alzheimer Disease / physiopathology
Alzheimer Disease / prevention & control*
Biomedical Research / standards
Biomedical Research / trends
Clinical Trials as Topic / methods
Clinical Trials as Topic / standards
Cognition Disorders / drug therapy*
Cognition Disorders / physiopathology
Disease Management*
Disease Progression
Drug Design
Early Diagnosis
Humans
Outcome Assessment, Health Care / methods
Outcome Assessment, Health Care / standards
Risk Reduction Behavior*